



EXPRESS MAIL NO. EV741779426US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Alan Verkman et al.  
Application No. : 10/676,727  
Filed : September 30, 2003  
For : CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE  
REGULATOR PROTEIN INHIBITORS AND USES THEREOF  
Examiner : Phyllis G. Spivack  
Art Unit : 1614  
Docket No. : 920085.401  
Date : July 27, 2006

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Supplemental Information Disclosure Statement. Copies of the cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the U.S. Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of that is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Third Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

A fee of \$180 is submitted in accordance with 37 C.F.R. 1.97(c). The Director is authorized to charge any other fees that may be required, or credit any overpayment to Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



---

Mae Joanne Rosok

Registration No. 48,903

MJR:ljt

Enclosures:

Check


Third Supplemental Information Disclosure Statement

Cited References (2)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

V813156

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>THRID SUPPLEMENTAL</b> <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				ATTY. DOCKET NO. <b>920085.401</b>		APPLICATION NO. <b>10/676,727</b>	
				APPLICANTS <b>Alan Verkman et al.</b>			
				FILING DATE <b>September 30, 2003</b>		GROUP ART UNIT <b>1614</b>	



U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
	AK				YES	NO
	AL					
	AM					
	AN					
	AO					

OTHER ART <small>(Including Author, Title, Date, Pertinent Pages, Etc.)</small>		
	AP	Roman, O.M. et al., "Synthesis and anti-inflammatory activity of 3-aryl-5-arylidene-2-thioxothiazolidine-4-ones," <i>Farmatsevtichnii Zhurnal (Kiev)</i> (3): 56-59, 2002.
	AQ	Roman, O.M. et al., "Synthesis and anti-inflammatory activity of 3-aryl-5-arylidene-2-thioxothiazolidine-4-ones," <i>Farmatsevtichnii Zhurnal (Kiev)</i> (3): 56-59, 2002. <b>English Translation.</b>
	AR	

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).